News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Sage Therapeutics, Inc.
< Previous
1
2
Next >
Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone
March 08, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
February 28, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics Announces European Medicines Agency Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
February 22, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress
February 16, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
February 06, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
BIIB
SAGE
Sage Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
February 02, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics to Provide Update on 2023 Key Initiatives at 41st Annual J.P. Morgan Healthcare Conference
January 08, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
January 03, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
December 06, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
BIIB
SAGE
Sage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
November 23, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone
November 22, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics to Present at the Stifel 2022 Healthcare Conference
November 09, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
November 08, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
October 25, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress
October 17, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone
September 19, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
September 02, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
August 02, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics to Present at Upcoming August Investor Conferences
August 01, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
July 19, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics to Present at Upcoming June Investor Conferences
June 02, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints
June 01, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics to Present at Bank of America Securities 2022 Healthcare Conference
May 04, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics Announces First Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
May 03, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)
May 02, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
BIIB
SAGE
Sage Therapeutics to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022
April 19, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 LUMINARY Study of SAGE-718 in Patients with Mild Cognitive Impairment and Mild Dementia due to Alzheimer’s Disease
April 01, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics to Present at 2022 Stifel CNS Days
March 22, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics Announces Presentation of Encouraging Results from the Phase 2 PARADIGM Study (Part A) of SAGE-718 in Patients with Mild Cognitive Impairment due to Parkinson’s Disease
March 15, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Highlights Pipeline and Business Progress
February 24, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.